Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Novo Nordisk, which produces Wegovy and Ozempic, said roughly 9,000 roles would be cut, with 5,000 of these reductions expected in Denmark.
UsenB
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Images
Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce.
"Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company's growth opportunities in diabetes and obesity," the company, which produces the Wegovy weight loss medication, said in a statement,
"As part of the transformation, Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark."
The company said the headcount reduction would incur a one-off cost of 8 billion Danish kroner ($1.26 billion).
As a result of the one-off costs, the company said its now expect full-year operating profit growth of 4% to 10%, down from the 10% to 16% outlined in its second-quarter results in August.
This is a developing story and will be updated shortly.
